Strategies and challenges for the next generation of therapeutic antibodies
Top Cited Papers
- 1 May 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 10 (5), 345-352
- https://doi.org/10.1038/nri2747
Abstract
More than 30 monoclonal antibody-based therapies have been approved for clinical use in the past 25 years. By looking at the strategies that have been used by pharmaceutical companies to develop these products, this Timeline article provides insight into the challenges that will be faced in developing the next generation of therapeutic antibodies. Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.Keywords
This publication has 75 references indexed in Scilit:
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2009
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding SiteScience, 2009
- Antibody-drug conjugates ace the tolerability testNature Biotechnology, 2008
- Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 SubclassOnline Journal of Public Health Informatics, 2008
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family membersOncogene, 2008
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986